WallStreetZenWallStreetZen

NASDAQ: ADPT
Adaptive Biotechnologies Corp Stock

$3.82-0.03 (-0.78%)
Updated Feb 21, 2024
ADPT Price
$3.82
Fair Value Price
N/A
Market Cap
$553.03M
52 Week Low
$2.61
52 Week High
$9.17
P/E
-2.81x
P/B
1.53x
P/S
4.39x
PEG
N/A
Dividend Yield
N/A
Revenue
$179.69M
Earnings
-$195.94M
Gross Margin
59.6%
Operating Margin
-101.04%
Profit Margin
-109%
Debt to Equity
0.98
Operating Cash Flow
-$159M
Beta
1.54
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

ADPT Overview

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ADPT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ADPT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ADPT is good value based on its book value relative to its share price (1.53x), compared to the US Biotechnology industry average (5.97x)
P/B vs Industry Valuation
ADPT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ADPT due diligence checks available for Premium users.

Be the first to know about important ADPT news, forecast changes, insider trades & much more!

ADPT News

Valuation

ADPT fair value

Fair Value of ADPT stock based on Discounted Cash Flow (DCF)
Price
$3.82
Fair Value
$4.79
Undervalued by
20.24%
ADPT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ADPT price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.81x
Industry
16.04x
Market
28.8x

ADPT price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.53x
Industry
5.97x
ADPT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ADPT's financial health

Profit margin

Revenue
$37.9M
Net Income
-$50.3M
Profit Margin
-132.7%
ADPT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ADPT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$717.7M
Liabilities
$356.0M
Debt to equity
0.98
ADPT's short-term assets ($435.24M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ADPT's short-term assets ($435.24M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ADPT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$46.7M
Investing
$26.1M
Financing
$17.0k
ADPT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ADPT vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ADPT$553.03M-0.78%-2.81x1.53x
BMEA$547.37M-9.56%-4.58x2.74x
URGN$546.03M-8.06%-4.15x-13.00x
ORIC$562.97M-1.53%-5.19x2.28x
MRNS$532.09M+2.20%-3.51x9.76x

Adaptive Biotechnologies Stock FAQ

What is Adaptive Biotechnologies's quote symbol?

(NASDAQ: ADPT) Adaptive Biotechnologies trades on the NASDAQ under the ticker symbol ADPT. Adaptive Biotechnologies stock quotes can also be displayed as NASDAQ: ADPT.

If you're new to stock investing, here's how to buy Adaptive Biotechnologies stock.

What is the 52 week high and low for Adaptive Biotechnologies (NASDAQ: ADPT)?

(NASDAQ: ADPT) Adaptive Biotechnologies's 52-week high was $9.17, and its 52-week low was $2.61. It is currently -58.34% from its 52-week high and 46.64% from its 52-week low.

How much is Adaptive Biotechnologies stock worth today?

(NASDAQ: ADPT) Adaptive Biotechnologies currently has 144,772,751 outstanding shares. With Adaptive Biotechnologies stock trading at $3.82 per share, the total value of Adaptive Biotechnologies stock (market capitalization) is $553.03M.

Adaptive Biotechnologies stock was originally listed at a price of $40.30 in Jun 27, 2019. If you had invested in Adaptive Biotechnologies stock at $40.30, your return over the last 4 years would have been -90.52%, for an annualized return of -44.51% (not including any dividends or dividend reinvestments).

How much is Adaptive Biotechnologies's stock price per share?

(NASDAQ: ADPT) Adaptive Biotechnologies stock price per share is $3.82 today (as of Feb 21, 2024).

What is Adaptive Biotechnologies's Market Cap?

(NASDAQ: ADPT) Adaptive Biotechnologies's market cap is $553.03M, as of Feb 22, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Adaptive Biotechnologies's market cap is calculated by multiplying ADPT's current stock price of $3.82 by ADPT's total outstanding shares of 144,772,751.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.